Menu
Search
|

Menu

Close
X

ReShape Lifesciences Inc RSLS.OQ (NASDAQ Stock Exchange Capital Market)

1.46 USD
-0.03 (-2.01%)
As of Jul 20
chart
Previous Close 1.49
Open 1.48
Volume 10,187
3m Avg Volume 42,210
Today’s High 1.50
Today’s Low 1.45
52 Week High 78.00
52 Week Low 1.33
Shares Outstanding (mil) 8.29
Market Capitalization (mil) 17.00
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, USD)
FY18
1
FY17
1
FY16
1
FY15
0
EPS (USD)
FY18
-5.443
FY17
-56.977
FY16
-1,717.324
FY15
-4,746.921
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
29.74
5.73
Price to Book (MRQ)
vs sector
0.45
5.47
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
0.00
16.84
LT Debt to Equity (MRQ)
vs sector
0.00
12.51
Return on Investment (TTM)
vs sector
-117.87
14.61
Return on Equity (TTM)
vs sector
-146.36
16.34

EXECUTIVE LEADERSHIP

Dan Gladney
Chairman of the Board, President, Chief Executive Officer, Since 2016
Salary: $459,167.00
Bonus: --
Scott Youngstrom
Chief Financial Officer, Chief Compliance Officer, Since 2016
Salary: $65,000.00
Bonus: --
Naqeeb Ansari
Senior Vice President - Sales, Since 2016
Salary: --
Bonus: --
Paul Hickey
Senior Vice President - Marketing and Reimbursement, Since 2016
Salary: --
Bonus: --
Peter Delange
Senior Vice President - Operations and Business Development, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Advanced Medical Equipment & Technology
Address:

1001 Calle Amanecer
SAN CLEMENTE   CA   92673-6260

Phone: +1949.4296680

ReShape Lifesciences Inc., formerly EnteroMedics Inc., is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company's neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve. The Company's initial product is the Maestro Rechargeable System, which uses VBLOC therapy to limit the expansion of the stomach, help control hunger sensations between meals, reduce the frequency and intensity of stomach contractions and produce a feeling of early and prolonged fullness. The Company's VBLOC therapy is designed to block the gastrointestinal effects of the vagus nerve by replicating a vagotomy using high-frequency, low-energy electrical impulses to intermittently interrupt naturally occurring neural impulses on the vagus nerve between the brain and the digestive system.

SPONSORED STORIES